Page 3 - இஸ்ரேலி ப்ரெஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from இஸ்ரேலி ப்ரெஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In இஸ்ரேலி ப்ரெஸ் Today - Breaking & Trending Today

Kadimastem Announces Executive Management Changes


Kadimastem Announces Executive Management Changes
USA - English
Accomplished US Life Science and Biotech Executive Asaf Shiloni Named New CEO
Company Appoints Biotech Industry Leaders Ronen Twito, CPA as Co-Chairperson and Doron Birger and Ron Mayron to the Company s Board of Directors
News provided by
Share this article
NESS ZIONA, Israel, Feb. 1, 2021 /PRNewswire/  
Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company, announces the appointment of Asaf Shiloni as CEO. This follows a series of executive management appointments in the last month including Mr. Ronen Twito, CPA, as Co-Chairperson of Kadimastem s Board of Directors, and new expert Board members, Mr. Doron Birger and Mr. Ron Mayron. All are highly accomplished biotechnology industry experts, dedicated to working in concert to secure a bright future for the company. ....

Israel General , City Of , United Kingdom , Hebrew University , Tel Aviv , Doron Birger , Yossi Nizhar , Ronen Twito , Bioblast Pharma , Ron Mayron , Asaf Shiloni , Gil Kraiem , Company Contacts , London Stock Exchange , Weizmann Institute Of Science , Kadimastem Co , Ben Gurion University , College Of Management Academic , Teva Pharmaceutical Industries , Tel Aviv Stock Exchange , Tel Aviv University , Must Have Communications , Professor Michel Revel , Chief Scientist , Israel Prize , Accomplished New Directors ,

Kadimastem Announces Encouraging Results of Cohort B of its Phase 1/2a Clinical Trial of AstroRx® for ALS


Kadimastem Announces Encouraging Results of Cohort B of its Phase 1/2a Clinical Trial of AstroRx® for ALS
USA - English
No treatment-related serious adverse events nor dose-limiting toxicities were reported during the 6- month post-treatment follow up
Clinically meaningful decline in disease progression was observed during the first 3-month of the 6-month follow up period, consistent with the results reported previously for Cohort A
News provided by
Share this article
Share this article
NESS ZIONA, Israel, Dec. 15, 2020 /PRNewswire/  Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company, announced today encouraging results of Cohort B of its Phase 1/2a clinical trial of AstroRx ....

Israel General , Ein Kerem , Tel Aviv , Marc Gotkine , Yossi Nizhar , Gil Kraiem , Company Contacts , Therapy Development Institute , Foundation For Life , Hadassah Medical Center , Weizmann Institute Of Science , Department Of Neurology At Hadassah Medical Center , Tel Aviv Stock Exchange , Must Have Communications , Rating Scale Revised , Principal Investigator , Michel Revel , Embryonic Stem Cells , Amyotrophic Lateral Sclerosis , Lateral Sclerosis , Development Institute , Human Embryonic Stem Cells , Professor Emeritus , Molecular Genetics , Weizmann Institute , Professor Revel ,

Vaccination - Israel National News

Vaccination - Israel National News
israelnationalnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from israelnationalnews.com Daily Mail and Mail on Sunday newspapers.

Kobi Finkler , Ben Ariel , Drug Administration , Health Ministry , Israeli Press , Sheva North America , பென் ஏரியல் , ஆரோக்கியம் அமைச்சகம் , இஸ்ரேலி ப்ரெஸ் , ஷெவா வடக்கு அமெரிக்கா ,